Antisense-Mediated Gene Therapy Targeting DMPK Restores Cardiac Ion Channel Function and Electrical Stability in Myotonic Dystrophy Type 1

Q: What is the clinical evidence from this study?

Population: Myotonic dystrophy type 1 (DM1). Intervention: IONIS-486178. Primary outcome: DMPK knockdown.

Q: What does this research mean for the field?

Antisense oligonucleotide-mediated suppression of DMPK with IONIS-486178 achieves approximately 90% knockdown, reduces toxic nuclear foci, corrects SCN5A mis-splicing, and reverses core electrophysiological defects in human induced pluripotent stem cell-derived cardiomyocytes from patients with Myotonic Dystrophy Type 1. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

Marion Pierre; Fabien Sourisseau; Dominic Jauvin; Valérie Pouliot; Michele Carrer; Paymaan Jafar-Nejad; Mohamed Boutjdir; Mohamed Chahine

doi:10.1016/j.hrthm.2026.06.003

June 1, 2026Heart Rhythm

Antisense-Mediated Gene Therapy Targeting DMPK Restores Cardiac Ion Channel Function and Electrical Stability in Myotonic Dystrophy Type 1

View Full Paper

Ask AI

Bookmark

Share

Graphical abstract published by Heart Rhythm — Graphical abstract · Published by Heart Rhythm · CC BY-NC-ND 4.0

Why the study?

Myotonic dystrophy type 1 leads to cardiac conduction defects and life-threatening arrhythmias, but current therapeutic options remain limited.

Does IONIS-486178 improve molecular and electrophysiological defects in human induced pluripotent stem cell-derived cardiomyocytes from a DM1 patient?

Key Points

The study aims to assess the efficacy of IONIS-486178, an antisense oligonucleotide, in correcting cardiac defects in myotonic dystrophy type 1.
Human induced pluripotent stem cell-derived cardiomyocytes from a DM1 patient were treated with IONIS-486178 for 24 hours.
Efficacy was assessed using RT-qPCR, FISH, western blot, and whole-cell patch-clamp techniques.
Approximately 90% DMPK knockdown was achieved, alongside reduced toxic nuclear foci.
Restoration of all ionic currents and action potential parameters was noted following treatment with IONIS-486178.

Structured PICO

Does IONIS-486178 improve molecular and electrophysiological defects in human induced pluripotent stem cell-derived cardiomyocytes from a DM1 patient?

P

Population

Human induced pluripotent stem cell-derived cardiomyocytes generated from a patient with myotonic dystrophy type 1.

I

Intervention

IONIS-486178 (5μmol/L), an antisense oligonucleotide (ASO) targeting mutant DMPK transcripts, treated for 24 hours

O

Outcome

Molecular and electrophysiological efficacy (assessed via DMPK knockdown, splicing analysis, nuclear foci quantification, ion channel protein expression, ionic currents, and action potential characterization)surrogate

Implication

ASO-mediated suppression of DMPK reverses core electrophysiological defects in a human cellular model of Myotonic Dystrophy Type 1, validating it as a potential therapeutic target for DM1-associated cardiac complications.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pierre et al. (2026) studied Myotonic dystrophy type 1 (DM1). IONIS-486178 was evaluated on DMPK knockdown.

synapsesocial.com/papers/6a23be4771a5da9775e77cc3 https://doi.org/10.1016/j.hrthm.2026.06.003

View Full Paper

Ask AI

Bookmark

Share

Antisense-Mediated Gene Therapy Targeting DMPK Restores Cardiac Ion Channel Function and Electrical Stability in Myotonic Dystrophy Type 1

Key Points

Structured PICO

Implication

Discussion

Cite This Study

Antisense-Mediated Gene Therapy Targeting DMPK Restores Cardiac Ion Channel Function and Electrical Stability in Myotonic Dystrophy Type 1

Key Points

Structured PICO

Implication

Discussion

Cite This Study

Keep reading

Keep reading